The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2023 | Predictors of ESA failure in patients with LR-MDS with severe anemia
Matteo Della Porta, MD, Humanitas University and Research Hospital, Milan, Italy, discusses the biomarkers associated with erythropoiesis stimulating agent (ESA) failure in patients with lower-risk myelodysplastic syndromes (MDS) with severe anemia, This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
